Published in final edited form as:

Bioorg Med Chem. 2007 March 1; 15(5): 2167–2176.

Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1

Chengguo Xing, Ph.D.

University of Minnesota

Liangyou Wang, XiaoHu Tang, and Yuk Y Sham

Abstract

A series of inhibitors for anti-apoptotic Bcl-2 proteins based on BHI-1 were synthesized and their binding interactions with Bcl-2, Bcl-X_L, and Bcl-w were evaluated. It was found that modification of BHI-1 resulted in varied binding profiles among Bcl-2, Bcl-X_L, and Bcl-w and a set of inhibitors with varied selectivity to Bcl-2, Bcl-X_L, and Bcl-w protein have been identified. Molecular modeling of the interaction of the BHI-1 based analogs with the anti-apoptotic Bcl-2 proteins suggested that the binding site for the BHI-1 based inhibitor was the least conserved section among Bcl-2, Bcl-X_L, and Bcl-w: targeting the non-conserved section may account for the observed selectivity of the BHI-1 based inhibitors among the anti-apoptotic Bcl-2 proteins. The validity of the model was supported by a strong correlation between the model-calculated binding energy and the experimental binding affinity. In summary, our studies suggest that most of the reported inhibitors for anti-apoptotic Bcl-2 proteins are nonselective and BHI-1 is a promising template to distinguish among Bcl-2, Bcl-X_L, and Bcl-w by targeting the nonconserved domain among the anti-apoptotic Bcl-2 proteins. Molecular-modeling aided rational development of BHI-1 based selective inhibitor for anti-apoptotic Bcl-2 proteins is underway.

Keywords

apoptosis; Bcl-2; inhibitor; selectivity

Introduction

Drug resistance is one major barrier in the fight against cancer.¹ At the molecular level, drug resistance can be acquired through the over-expression of anti-apoptotic Bcl-2 proteins which protect cancer cells from apoptosis induced by cancer therapy.²⁻⁴ Inhibiting anti-apoptotic Bcl-2 proteins, therefore, holds promise as a way to overcome drug resistance for cancer treatment. This concept has been proved valid through anti-sense approach.⁵⁻⁷

Anti-apoptotic Bcl-2 proteins are a subgroup of the Bcl-2 protein family, including Bcl-2, Bcl-X_L, Bcl-w, Mcl-1, and A1. In some cancers, more than one anti-apoptotic Bcl-2 protein is co-over-expressed.⁸⁻¹⁰ Under such circumstance, a non-selective inhibitor for multiple antiapoptotic Bcl-2 proteins may be needed to antagonize these proteins simultaneously to overcome the drug resistance. Some cancers, however, exhibit exclusive over-expression of one specific anti-apoptotic Bcl-2 protein.¹¹⁻¹⁵ For instance, in a study of head and neck

Corresponding Author: Dr. Chengguo Xing, Ph.D.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

carcinoma by Thompson et al, 52% of the patients had up-regulated Bcl-X_L and 17% of the patients had upregulated Bcl-2. There was no overlap between these two groups.¹² In Kaposi's sarcoma, the expression level of Bcl-X_L protein was elevated, while Bcl-2 protein remained at the basal level.¹³ In mastocytosis, the expression of Bcl-2 significantly increased while no up-regulation of Bcl-X_L was detected.¹⁶ In gastric and colorectal adenocarcinomas, only Bcl-w was upregulated.^{14,15} Besides their selective over-expression in cancer tissues, anti-apoptotic Bcl-2 proteins are expressed in healthy tissues in a tissue-selective manner¹⁷⁻¹⁹ and function to protect healthy cells.¹⁹ The cancer/tissue-selective expression of anti-apoptotic Bcl-2 proteins suggests that as therapeutic agents, member-selective inhibitors for anti-apoptotic Bcl-2 proteins could be safer than the non-selective counterparts in those tumors with the selective elevation of one single anti-apoptotic Bcl-2 protein. However, it is still debatable whether the selective inhibitor will be as effective as the non-selective ones in overcoming drug resistance. To address these questions, selective inhibitors and non-selective inhibitors of the same class need to be developed. In addition, the selective inhibitors for the anti-apoptotic Bcl-2 proteins can be useful chemical probes to help define the biological functions of the individual anti-apoptotic Bcl-2 proteins.

Mechanistically, anti-apoptotic Bcl-2 proteins protect cells from apoptosis by antagonizing pro-apoptotic Bcl-2 proteins through dimerization.^{20,21} Structural studies of a complex of Bcl-X_L protein and a pro-apoptotic peptide (Bak BH3) have revealed a hydrophobic cleft on Bcl-X_L protein as the binding pocket for the pro-apoptotic peptide²² and molecules binding to that hydrophobic cleft may overcome the protective effect of the Bcl-X_L protein.²³ These observations have stimulated the recent discovery of several small molecules targeting the hydrophobic cleft of Bcl-X_L or Bcl-2 proteins with a partial list shown in Figure 1.²⁴⁻³² As the hydrophobic cleft is very conserved among the anti-apoptotic Bcl-2, Bcl-X_L, Bcl-w, and Mcl-1 proteins,^{22,33-36} these reported inhibitors could have cross activities among these anti-apoptotic Bcl-2 proteins as has been established for ABT-737.³⁰ However, it is possible to develop selective inhibitors among the anti-apoptotic Bcl-2 proteins as the anti-apoptotic Bcl-2 proteins can differentiate the peptides derived from the BH3 domain of the pro-apoptotic Bcl-2 proteins with selectivity up to 10 fold.^{37,38} In addition, a small-molecule inhibitor (YC-137) was recently discovered by Wang et al recently to selectively target Bcl-2 protein over Bcl-X_L protein.²⁹ Biological evaluation of YC-137 demonstrated that YC-137 can selectively eliminate the tumors with the over-expression of Bcl-2 protein over those with the over-expression of Bcl-X_L protein. More excitingly, YC-137 showed minimal toxicity to the normal healthy cells with no elevation of Bcl-2 protein, further underscoring the need to develop selective inhibitors for anti-apoptotic Bcl-2 proteins.

Since there is no obvious structural similarity among the reported inhibitors, we hypothesized that their respective interactions with anti-apoptotic Bcl-2 proteins involve distinct sections along the long hydrophobic cleft. Inhibitors targeting the less conserved portion of the hydrophobic cleft would be more promising templates in the search for member-selective inhibitors. With initial NMR and molecular modeling study suggesting that BHI-1 targets the less conserved section of the hydrophobic cleft,²⁵ BHI-1 was selected for study to investigate its potential as lead templates for developing member-selective inhibitors for anti-apoptotic Bcl-2 proteins.

Results and Discussion

Chemistry

A group of BHI-1 analogs (compounds **3a-o**) possessing variation at the amino acid and alkylidene sections were synthesized with a 20 - 40% overall yield by first cyclizing respective amino acids with CS₂ and α -chloroacetate to form rhodanines by using a procedure similar to that previously reported,³⁹ followed by Knoevenagel condensation of rhodanines with varied

aldehydes or ketones to form the final analogues (Scheme 1). The condensation generated two isomers (E and Z) and the major product was the thermodynamically stable Z isomer as characterized by the down-field shift of the methylene proton of the Z isomer compared to that of the E isomer. No racemization was detected in the synthesis of the BHI-1 analogs as demonstrated in the Supplementing Materials.

Biology

The binding affinities of the synthesized small molecules and several reported inhibitors to three anti-apoptotic Bcl-2 proteins, Bcl-2, Bcl-X_L, and Bcl-w, were determined by using a fluorescence polarization (FP) based competition assay against an Oregon Green fluoresceinlabeled Bak BH3 domain peptide (Flu-Bak).²⁵ First, the binding affinities of the Flu-Bak peptide to the three Bcl-2 proteins were determined by using a Saturation binding model with a constant concentration of Flu-Bak peptide (45nM) and varied concentrations of the proteins. The binding affinity of Flu-Bak peptide to the three Bcl-2 proteins are summarized in Table 1. The binding affinity of Flu-Bak peptide to Bcl-X_L protein ($K_d = 362 \pm 36$ nM) is comparable to the binding affinity determined by Sattler et al, $K_d = 340$ nM.²² While the binding affinity of Flu-Bak peptide to Bcl-2 determined in this study ($K_d = 6200 \pm 1500$ nM) is quite different from the one determined by Gemperli et al ($K_d = 900 \pm 100$ nM),³⁷ it is possible that the difference is because of the different forms of recombinant Bcl-2 proteins are used in these two studies. The recombinant Bcl-2 protein used in this study is transmembrane-domain deleted. With the binding affinities of Flu-Bak peptide to the proteins determined, the interactions of BHI-1 based small molecules to the Bcl-2 proteins were indirectly evaluated by assaying their capabilities of competing against Flu-Bak peptide binding to the Bcl-2 proteins. The capabilities of the small molecules to compete against Flu-Bak peptide binding to Bcl-2 proteins (K_i) are summarized in Table 2 for reported inhibitors and Table 3 for BHI-1 based inhibitors.

As we have hypothesized, the reported inhibitors bound to all the three anti-apoptotic Bcl-2 proteins tested without much selectivity. In our effort to identify an optimal template for the search of selective inhibitors, a series of analogs of BHI-1 were synthesized. Of note, modifications resulted in a wider range of binding affinities (1.95 μ M - 848 μ M) and modification also changed the binding profiles of these inhibitors for Bcl-2, Bcl-X_L, and Bcl-w proteins. For instance, **3e** and **3g** are more selective for Bcl-X_L, L-Phe esters (**3n** and **3o**) are more selective for Bcl-w, while **3c** and the ketone analogues (**3f**, **3h**, **3i**, **3j**, and **3k**) are selective for Bcl-2 with **3c** > 10-fold selective for Bcl-2 over both Bcl-X_L and Bcl-w. The distinct binding profiles of BHI-1 based inhibitors among Bcl-2, Bcl-X_L, and Bcl-w suggest that BHI-1 is a promising template for the development of selective inhibitors.

Molecular modeling

To understand the observed binding selectivity of BHI-1 based inhibitors for Bcl-2, Bcl-X_L, and Bcl-w, molecular modeling of the binding interaction by InsightII was performed to define the binding section in the hydrophobic cleft on the proteins for these small molecules. The validity of the model first was evaluated by correlating 1) the model-estimated binding energies of the inhibitors to the protein with 2) experimentally-determined binding affinities; the estimated binding energy correlates highly with the experimental binding affinity (Figure 2 shows the correlation for seven BHI-1 based inhibitors for Bcl-X_L protein, $R^2 = 0.88$; similar correlations were obtained when Bcl-2 and Bcl-w homology models were used for docking as well). The high correlation between modeled and experimental results suggested that the binding model likely reflects the actual binding interactions.

Figure 3 A shows the modeled three-dimensional structure of one BHI-1 candidate (**3e**) bound to Bcl-X_L protein. Based upon sequence alignment of Bcl-2, Bcl-X_L, and Bcl-w, the major

distinctions among these three proteins in the hydrophobic cleft are amino acids 104, 108, and 122 (Table 4, Amino acids numbered based on Bcl-X_L sequence).⁴⁰ Amino acids 104 and 108 are located at the modeled binding site for BHI-1 based inhibitors while amino acid 122 is ~ 2-6 Å from **3k** inhibitor (Figure 4 B). The modeling studies suggest that BHI-1 based inhibitors bind to the least conserved section of the hydrophobic cleft. The distinct D104 in Bcl-2 protein indicates that incorporating basic functional groups that will be protonated at physiological pH at the amino acid section of BHI-1 template will introduce binding preference to Bcl-2 and may account for the observed selective binding of **3c** to Bcl-2 protein. A104 and L108 on Bcl-X_L may be responsible for the moderate selectivity of **3e** and **3g** for Bcl-X_L because of steric effects and hydrophobic interactions. Interestingly, all of the analogues with a R2 substituent prefer Bcl-2 and we hypothesize that this selectivity trend is due to the relative wideness of the cleft among Bcl-2, Bcl-X_L, and Bcl-w; because Bcl-X_L has the narrowest cleft followed by Bcl-2, with Bcl-w the widest,⁴⁰ the analogues with a R2 substituent may fit well into the hydrophobic cleft of Bcl-2 while they are too bulky for Bcl-X_L and not big enough for Bcl-w. Incorporation of larger substituents is expected to result in analogs selective for Bcl-w. This spatial difference of the hydrophobic cleft also explains the selectivity of **3n** and **3o** for Bcl-w, while **3l** and **3m** do not bind Bcl-w selectively.

Conclusion

In this study, we evaluated the binding interactions of several reported inhibitors for antiapoptotic Bcl-2 proteins with Bcl-2, Bcl-X_L, and Bcl-w proteins. None of these inhibitors showed selectivity among the three anti-apoptotic Bcl-2 proteins. We also synthesized and evaluated a series of analogues based upon BHI-1 to search for selective inhibitors for the anti-apoptotic Bcl-2 proteins, as BHI-1 targets the less conserved section of the hydrophobic cleft. Our results suggest that modifications of BHI-1 can introduce dramatic binding affinity changes and varied binding profile among Bcl-2, Bcl-X_L, and Bcl-w proteins. Modeling of the binding interaction of this series of analogues with the three proteins supports that the binding site for BHI-1 is the least conserved section in the long hydrophobic cleft. The model also explains the observed binding selectivity of BHI-1 based inhibitors for Bcl-2, Bcl-X_L, and Bcl-w proteins. Molecular-modeling-aided rational design of member-selective inhibitors based on the BHI-1 template is in progress.

Experimental Section

Preparation of recombinant Bcl-2, Bcl-X_L, and Bcl-w proteins

The DNA sequence encoding Bcl-2ΔC21 inserted into a His₆ tag fused pET-25b(+) vector was a generous gift from Stanley Korsmeyer at Harvard University; the DNA sequence encoding Bcl-wΔC22 and the DNA sequence encoding Bcl-X_LΔloopΔC40 inserted into a His₆ tag fused pET-29b(+) vector were generous gifts from Kalle Gehring at McGill University. The plasmids were transformed into the *Escherichia coli* strain ER2566 (New England Biolab., MA). The expression of the fusion proteins was induced by 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and the fusion proteins were purified by Ni-NTA resin following a native protein purification protocol provided by manufacture (Qiagen, CA). Recombinant proteins were concentrated with Centrifugal Filter Devices (Millipore, MA) and dialyzed against phosphate buffered saline (PBS) containing 15% glycerol, 1 mM dithiothreitol (DTT). The concentration of the recombinant protein was determined by the Bradford method with bovine serum albumin (BSA) as a standard, and stored at -20 °C.

Fluorescence Polarization Assays (FPA)

The Bak BH3 (GQVGRQLAIGDDINR) peptide was synthesized at The Oligonucleotide & Peptide Synthesis Facility at the University of Minnesota, purified by HPLC. The purified peptide was labeled with Oregon Green 488® fluorescein at the N terminus following the

manufacture's protocol (Promega, CA), purified by HPLC, analyzed by mass spectrometry (Calculated: 2119 Da; Observed: 2119.7 Da), and named as Flu-Bak. Flu-Bak was dissolved in double distilled water and stored at -20 °C as aliquot. FPA were conducted with the Flu-Bak peptide by using a GENios Pro plate reader (Tecan US, NC) with all assays performed in triplicate and each assay performed twice.

To determine the binding affinity of the Flu-Bak peptide for an anti-apoptotic Bcl-2 protein, a series of 3-fold dilutions of the anti-apoptotic Bcl-2 protein was prepared in a PBS solution, pH 7.0 with 45 nM Flu-Bak peptide and 1 mM DTT, and incubated at 23 °C for one hour (a time-course study of binding process of Flu-Bak peptide to all the anti-apoptotic Bcl-2 proteins demonstrated that binding interaction reaches equilibrium within 5 min). To each well in a 96-well half-area black plate (Corning, NY) the solution (50 µl) was added and fluorescence polarization (FP, in mP unit) was measured. The binding affinity was determined by fitting the FP values to the concentrations of protein with a single-binding site saturation model, by using Prism software package (GraphPad, CA).⁴¹

To determine the binding affinity of small molecules for an anti-apoptotic Bcl-2 protein, a series of 3-fold dilutions of small molecules were prepared in dimethylsulfoxide, i.e., 10 mM, 3.33 mM, 1.11 mM, 0.37 mM, 0.123 mM, 0.041 mM, 0.014 mM, and 0 mM. To each well in a 96-well half-area black plate, 5 µl of the small molecule stock solution was added. A solution containing 50 nM Flu-Bak peptide and the anti-apoptotic Bcl-2 protein to be tested in PBS buffer, pH 7.0, 1 mM DTT was prepared and incubated at 23 °C for one hour. The concentration of the anti-apoptotic Bcl-2 protein used corresponds to the one that resulted in 60% of Flu-Bak peptide complex with the anti-apoptotic Bcl-2 protein and such a concentration was determined in the Flu-Bak and Bcl-2 protein saturation binding experiment. There are two reasons that we chose the condition with 60% complex formation for the competing assay. First, with 60% complex formation, there will be a FP increase of > 100mP over the background. Such a FP increase would generate a considerable FP change in the presence of effective competition over background variation. Second, with 60% complex formation, relatively less competing ligand needs to be added to detect a considerable FP change comparing to the competition with higher percentage of complex formation. The corresponding concentrations of Bcl-2, Bcl-X_L, and Bcl-w needed to achieve 60% complex formation under the assay conditions are 1000 nM, 880nM, and 1200 nM respectively. To each well the Flu-Bak peptide and anti-apoptotic Bcl-2 protein solution (45 µl) was added by auto-injection at a rate of 200 µl/second. The sample was incubated at 23 °C for one hour and shaken for two seconds before fluorescence polarization (in mP unit) was measured. Controls included dose-response measurements in the absence of proteins to assess for any interactions between the compounds and the Flu-Bak peptide. Eventual effects were taken into account by subtraction. The inhibitory constant (K_i) was determined by fitting the FP changes to the concentration of the small molecule competing ligand by using an equation developed by Shaomeng Wang et al with GraphPad (Equation 1).⁴²

$$FP = \frac{FP_{\max}}{1 + X * K_d / (2 * K_i * L_0 + K_i * P_0 + K_i * K_d)} \quad \text{Equation 1}$$

FP_{max}: the fluorescence polarization value when 60% of Flu-Bak binds to the protein

FP: the fluorescence polarization value with the addition of the small molecule

K_d: dissociation constant of Flu-Bak to the protein

L₀: the total concentration of Flu-Bak peptide

P₀: the total concentration of protein

K_i: the inhibitory constant of the small molecule to the binding of Flu-Bak to protein

Molecular Modeling

Molecular modeling studies were conducted on a SGI Octane2 workstation using InsightII (Accelrys Inc., CA). The NMR energy minimized average structure of Bcl-X_L was extracted from the complex of Bcl-X_L and Bak peptide from the protein data bank (PDB code: 1BXL). The structures of Bcl-2 and Bcl-w used for modeling studies were generated by homology-mimicking the structure of Bcl-X_L from the complex of Bcl-X_L and Bak peptide based on sequence alignments (PDB code: 1G5M, 1BXL, and 1MK3 respectively for Bcl-2, Bcl-X_L, and Bcl-w) with side chains energy minimized. The structures of all the inhibitors were created and energy minimized within InsightII, followed by docking of the inhibitors into the Bak peptide binding site.²² The energy minimization of the ligand-protein complex was carried out by keeping the binding site rigid using a dielectric constant of 80. The binding energy of the ligand to the protein was calculated by using $\epsilon = 6$.

Chemistry

All commercial reagents and anhydrous solvents were purchased from vendors and were used without further purification or distillation, unless otherwise stated. Analytical thin-layer chromatography (TLC) was performed on EM Science silica gel 60 F₂₅₄ (0.25 mm). Compounds were visualized by UV light and/or stained with either *p*-anisaldehyde, potassium permanganate, or cerium molybdate solutions followed by heating. Flash column chromatography was performed on Fischer Scientific silica gel (230 - 400 mesh). Melting points were determined by using a Thomas Hoover capillary melting point apparatus. IR spectra were recorded on a Nicolet Portege 460 FT-IR instrument. NMR (¹H) spectra were recorded on a Varian 300 MHz spectrometer and calibrated using an internal reference. High-resolution mass spectra (HRMS) were recorded on a BrukerBio TOF II mass spectrometer. Reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on a Beckman Coulter System Gold 126 solvent module and 168 detector. Results were analyzed using the 32 Karat software package. Method MA1, MA2, MA3 and MB3 were used on a Celius C18 column, 4.6 × 150mm. Method MB1 and MB2 were used on a Phenomenex Polar-RP column, 4.6 × 250mm. Mobile phase A was 0.1% TFA in water, B1 was 0.1% TFA in acetonitrile, B2 was 0.1% TFA in methanol. Flow rate was 1.0mL/min. The run duration was 30 min. MA1 and MB1 were detected at 375nm; MA2 and MB2 were detected at 355nm; MA1 and MB3 were detected at 395nm. The time program for MA1 was 100% A(0-5min), 0-35% B1(5-7min), 35-95% B1(7-22min), 95% B1(22-29min), 95%-0B1(29-30min); MA2 was 100% A(0-5min), 0-65% B1(5-7min), 65-75% B1(7-22min), 75-80% B1(22-29min), 80%-0B1(29-30min); MA3 was 100% A(0-5min), 0-70% B1(5-7min), 70-80% B1(7-22min), 80-85% B1(22-29min), 85%-0B1(29-30min); MB1 was 100% A(0-5min), 0-95% B2(5-7min), 95% B2(7-29min), 95%-0B2(29-30min); MB2 was 100% A(0-5min), 0-85% B2(5-7min), 85% B2(7-29min), 85%-0B2(29-30min); MB3 was 100% A(0-5min), 0-80% B2(5-7min), 80%-90% B2(7-22min), 90-95% B2(22-29min), 95%-0B2(29-30min).

General procedure for synthesis of BHI-1 based inhibitors—In a round-bottom flask equipped with a magnetic stirrer, the amino acid or ester (1 mmol) was dissolved with sodium hydroxide (80 mg, 2 mmol) in water (10 ml). Then, carbon disulfide (60 μ l, 1 mmol) was added to the reaction mixture, which was stirred vigorously overnight. An aqueous solution of ClCH₂CO₂Na (1 ml, 1 M, 1 mmol) was added and stirring was continued at 23 °C for 3 hours. Then hydrochloric acid solution (3 ml, 5.5 N, 16.5 mmol) was added and the reaction mixture was refluxed overnight. The reaction mixture was neutralized with saturated NaHCO₃ solution. The solvent was removed under vacuum and the cyclized product was purified by flash chromatography. The cyclized intermediates are reported before and no characterization data is included herein.³⁹

General procedure for condensation with aldehydes/ketones—In a round-bottom flask equipped with a reflux condenser and a magnetic stirrer, cyclized rhodanine intermediate (1 mmol) in toluene (20 ml) was added. To this, the aldehyde/ketone (3 mmol) was added along with ammonium acetate (3 mmol). The mixture was refluxed overnight and the solvent was removed under vacuum. The final rhodanine candidate was purified by flash chromatography.

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-methylbutanoic acid (BHI-1)

(85%). TLC (CH_2Cl_2 / MeOH = 5:1), R_f 0.40. IR (KBr): 3700-2200, 2967, 2897, 1727, 1710, 1603, 1582, 1486, 1382, 1327, 1242, 1202, 1128, 1072, 1005, 815 cm^{-1} . ^1H NMR (CDCl_3): δ 7.62 (1H, s, 5'-dene proton), 7.57 (2H, d, J = 8.5 Hz, 2" and 6" Ph protons), 7.30 (2H, d, J = 8.5 Hz, 3" and 5" Ph protons), 5.34 (1H, m, 2-methine proton), 2.84 (1H, m, 3-methine proton), 1.25 (6H, d, J = 7.4 Hz, 3, 3-dimethyl protons); ESI-MS (negative): m/z 398, 400 (M^- -H).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3a)

(81%). Yellow powder. TLC (CH_2Cl_2 / MeOH = 10:1), R_f 0.11. m.p. 223-4 $^\circ\text{C}$. IR (KBr): 3700-2200, 2922, 1714, 1602, 1583, 1486, 1400, 1342, 1249, 1125, 1071, 1006, 829 cm^{-1} . ^1H NMR (CDCl_3): δ 7.64 (1H, s, 5'-dene proton), 7.62 (2H, d, J = 8.7 Hz, 2" and 6" Ph protons), 7.35 (2H, d, J = 8.7 Hz, 3" and 5" Ph protons), 5.79 (1H, m, 2-methine proton), 1.68 (3H, d, J = 7.6 Hz, 3-methyl protons); ESI-MS (negative): m/z 370, 372 (M^- -H). HRMS ($\text{C}_{13}\text{H}_9\text{BrNO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 369.9191, calcd m/z 369.9205; RP-HPLC method A1, minor isomer t_R = 19.150 min (2.19%) and major isomer t_R = 20.300 min (97.81%); method B1, minor isomer t_R = 15.083 min (2.12%) and major isomer t_R = 15.500 min (87.93%).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylthiobutanoic acid (3b)

(81%) TLC (CH_2Cl_2 / MeOH = 5:1), R_f 0.29. m.p. 165-6 $^\circ\text{C}$. IR (KBr): 3700-2200, 2922, 1714, 1602, 1583, 1486, 1400, 1342, 1249, 1125, 1071, 1006, 829 cm^{-1} . ^1H NMR (CDCl_3): δ 7.62-7.45 (3H, m, 5'-dene proton and 2" and 6" Ph protons), 7.28-7.24 (2H, d, J = 8.4 Hz, 3" and 5" Ph protons), 5.76 (1H, m, 2-methine proton), 2.60-2.26 (4H, m, 3- and 4-methylene protons), 2.01 (3H, s, 4-methylthio methyl protons); ESI-MS (negative): m/z 430, 432 (M^- -H); 386, 388 (M^- -H-CO₂). HRMS ($\text{C}_{15}\text{H}_{13}\text{BrNO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 429.9250, calcd m/z 429.9239; RP-HPLC method MA1, minor isomer t_R = 20.367 min (12.07%) and major isomer t_R = 21.483 min (87.93%); method MB1, minor isomer t_R = 15.767 min (12.67%) and major isomer t_R = 16.300 min (87.33%).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-(3-indolyl)-propanoic acid (3c)

(78%) Yellow powder. TLC (CH_2Cl_2 / MeOH = 5:1), R_f 0.24. m.p. 158-9 $^\circ\text{C}$. IR (KBr): 3700-2200, 2924, 1691, 1601, 1351, 1138 cm^{-1} . ^1H NMR (CDCl_3): δ 7.73 (2H, d, J = 8.4 Hz, 2" and 6" Ph protons), 7.62 (1H, d, J = 8.1 Hz, indole-7 proton), 7.60 (1H, s, 5'-dene proton), 7.48 (2H, d, J = 8.4 Hz, 3" and 5" Ph protons), 7.28 (1H, d, J = 8.1 Hz, indole-4 proton), 7.14-6.99 (2H, m, indole-5,6 protons), 7.00 (1H, s, indole-2 proton), 5.90 (1H, m, 2-methine proton), 4.04 (1H, dd, J_1 = 13.2 Hz, J_2 = 3.9 Hz, 3-methylene proton), 3.80 (1H, dd, J_1 = 13.2 Hz, J_2 = 3.9 Hz, 3-methylene proton); ESI-MS (negative): m/z 485, 487 (M^- -H); 441, 443 (M^- -H-CO₂); HRMS ($\text{C}_{21}\text{H}_{14}\text{BrNO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 484.9634, calcd m/z 484.9627; RP-HPLC method MA1, minor isomer t_R = 19.467 min (1.23%) and major isomer t_R = 20.250 min (98.73%); method MB1, minor isomer t_R = 14.700 min (5.44%) and major isomer t_R = 15.100 min (94.56%).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-glutaric acid (3d)

(76%) Yellow powder. TLC (CH_2Cl_2 / MeOH = 1:1), R_f 0.28. m.p. 227-8 $^\circ\text{C}$. IR (KBr): 3700-2200, 1700, 1602, 1487, 1401, 1345, 1252, 1174, 1073, 1008, 819 cm^{-1} . ^1H NMR (CD_3OD): δ 7.77 (2H, d, J = 8.4 Hz, 2" and 6" Ph protons), 7.70 (1H, s, 5'-dene proton), 7.57

(2H, d, $J = 8.4$ Hz, 3'' and 5'' Ph protons), 5.64 (1H, m, 2-methine proton), 2.30-2.04 (4H, m, 3 and 4-methylene protons); ESI-MS (negative): m/z 428, 430 (M^- -H). HRMS ($C_{15}H_{11}BrNO_5S_2$) [$M - H$] $^-$: found m/z 427.9268, calcd m/z 427.9260; RP-HPLC method MA1, minor isomer $t_R = 16.417$ min (15.06%) and major isomer $t_R = 17.333$ min (84.94%); method MB1, minor isomer $t_R = 13.900$ min (11.14%) and major isomer $t_R = 14.433$ min (92.53%).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-phenylpropanoic acid (3e)

(89%) Yellow powder. TLC (CH_2Cl_2 / MeOH = 10:1), R_f 0.13. m.p. 242-3 °C. IR (KBr): 3700-2200, 2923, 2361, 1700, 1600, 1487, 1400, 1342, 1239, 1174, 1073, 1008, 829, 700, 546 cm^{-1} . 1H NMR ($CDCl_3$): δ 7.64-7.32 (3H, m, 5'-dene proton and 2'' and 6'' Ph protons), 7.26-7.00 (7H, m, 3'' and 5'' Ph and 3-Ph protons), 5.93 (1H, m, 2-methine proton), 3.55 (2H, m, 3-methylene protons); ESI-MS (negative): m/z 446, 448 (M^- -H); 402, 404 (M^- -H- CO_2). HRMS ($C_{19}H_{13}BrNO_3S_2$) [$M - H$] $^-$: found m/z 425.9534, calcd m/z 445.9518; RP-HPLC method MA1, minor isomer $t_R = 21.050$ min (5.42%) and major isomer $t_R = 22.067$ min (94.58%); method MB1, minor isomer $t_R = 15.583$ min (6.80%) and major isomer $t_R = 16.167$ min (93.20%).

2-[5-(1-phenylbutylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-phenylpropanoic acid (3f)

(43%) Orange oil. TLC (Hexane / Ethyl acetate = 1:1), R_f 0.38. IR (KBr): 3700-2200, 3027, 2959, 2929, 2870, 1711, 1589, 1569, 1455, 1441, 1382, 1332, 1230, 1175, 1029, 970, 920, 751, 698 cm^{-1} . 1H NMR ($CDCl_3$): δ 7.43-7.18 (10H, m, 3-Ph and Ph'' protons), 6.05 (1H, m, 2-methine proton), 3.60 (2H, d, $J = 7.2$ Hz, 3-methylene protons), 3.17 (2H, m, $(CH_3CH_2CH_2)''$ protons), 1.41 (2H, m, $(CH_3CH_2CH_2)''$ protons), 0.94 (3H, t, $J = 7.2$ Hz, $(CH_3CH_2CH_2)''$ protons). ESI-MS (negative): m/z 410 (M^- -H). HRMS ($C_{22}H_{21}NO_3S_2$) [$M - H$] $^-$: found m/z 410.0892, calcd m/z 410.0883; RP-HPLC method MA2, minor isomer $t_R = 23.233$ min (35.97%) and major isomer $t_R = 23.983$ min (64.03%); method MB2, minor isomer $t_R = 22.717$ min (34.23%) and major isomer $t_R = 23.833$ min (65.77%).

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (3g)

(79%). Yellow powder. TLC (CH_2Cl_2 / MeOH = 10:1), R_f 0.22. m.p. 155-6 °C. IR (KBr): 3700-2200, 2956, 1716, 1700, 1601, 1558, 1341, 1273, 1239, 1207 cm^{-1} . 1H NMR ($CDCl_3$): δ 7.64 (1H, s, 5'-dene proton), 7.53 (2H, d, $J = 8.1$ Hz, 2'' and 6'' Ph protons), 7.23 (2H, d, $J = 8.1$ Hz, 3'' and 5'' Ph protons), 5.53 (1H, m, 2-methine proton), 2.00 (2H, m, 3-methylene protons), 1.23 (1H, m, 4-methine proton), 0.86 (6H, m, 4, 4-dimethyl protons); ESI-MS (negative): m/z 412, 414 (M^- -H); 358, 360 (M^- -H- CO_2). HRMS ($C_{16}H_{16}BrNO_3S_2$) [$M - H$] $^-$: found m/z 411.9702, calcd m/z 411.9675; RP-HPLC method MA1, minor isomer $t_R = 22.167$ min (9.20%) and major isomer $t_R = 23.433$ min (90.80%); method MB1, minor isomer $t_R = 15.317$ min (13.02%) and major isomer $t_R = 15.767$ min (86.98%).

2-[5-(1-phenylbutylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (3h)

(46%). Orange oil. TLC (Hexane / Ethyl acetate = 1:1), R_f 0.17. IR (KBr): 3700-2200, 2959, 2930, 2870, 1709, 1590, 1332, 1232, 1213 cm^{-1} . 1H NMR ($CDCl_3$): δ 7.51-7.20 (5H, m, Ph'' protons), 5.79 (1H, m, 2-methine proton), 3.21 (2H, m, $(CH_3CH_2CH_2)''$ protons), 2.20 (2H, m, $(CH_3CH_2CH_2)''$ protons), 2.01 (2H, m, 3-methylene protons), 1.60 (1H, m, 4-methine proton), 1.10-0.80 (9H, m, 4, 4-dimethyl and $(CH_3CH_2CH_2)''$ protons). ESI-MS (negative): m/z 376 (M^- -H). HRMS ($C_{19}H_{22}NO_3S_2$) [$M - H$] $^-$: found m/z 376.1050, calcd m/z 376.1039; RP-HPLC method MA1, minor isomer $t_R = 22.617$ min (37.27%) and major isomer $t_R = 22.083$ min (62.73%); method MB2, minor isomer $t_R = 22.733$ min (34.89%) and major isomer $t_R = 15.750$ min (63.11%).

2-[5-(1-phenylethylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (3i)

(38%). Orange oil. TLC (Hexane / Ethyl acetate = 1:1), R_f 0.17. IR (KBr): 3700-2200, 2957, 2869, 1708, 1591, 1570, 1490, 1442, 1331, 1213, 1141, 1028, 990, 760, 698 cm^{-1} . ^1H NMR (CDCl_3): δ 7.59-7.20 (5H, m, Ph" protons), 5.73 (1H, m, 2-methine proton), 2.72 (3H, s, 5-methyl" protons), 2.14 (2H, m, 3-methylene protons), 1.55 (1H, m, 4-methine proton), 0.95 (6H, m, 4, 4-dimethyl protons). ESI-MS (negative): m/z 348 (M^- -H). HRMS ($\text{C}_{17}\text{H}_{18}\text{NO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 348.0756, calcd m/z 348.0726; RP-HPLC method MA2, minor isomer t_R = 17.800 min (23.19%) and major isomer t_R = 18.983 min (76.81%); method MB2, minor isomer t_R = 19.183 min (27.46%) and major isomer t_R = 20.133 min (72.54%).

2-[5-(diphenylmethylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (3j)

(30%). Orange oil. TLC (Hexane / Ethyl acetate = 1:1), R_f 0.26. IR (KBr): 3700-2200, 3056, 2956, 2869, 1712, 1616, 1579, 1558, 1444, 1330, 1212, 1133, 1093, 752, 697 cm^{-1} . ^1H NMR (CDCl_3): δ 7.51-7.20 (10H, m, Ph", Ph" protons), 5.76 (1H, m, 2-methine proton), 2.16 (2H, m, 3-methylene protons), 1.60 (1H, m, 4-methine proton), 1.10-0.93 (6H, m, 4, 4-dimethyl protons). ESI-MS (negative): m/z 410 (M^- -H). HRMS ($\text{C}_{22}\text{H}_{20}\text{NO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 410.0896, calcd m/z 410.0883; RP-HPLC method MA1, t_R = 22.700 min; method MB1, t_R = 16.083 min.

2-[5-(phenyl(4-biphenyl)methylidene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (3k)

(23%). Orange oil. TLC (Hexane / Ethyl acetate = 1:1), R_f 0.19. IR (KBr): 3700-2200, 3029, 2956, 2869, 1712, 1352, 1330, 1213, 1179, 752, 697 cm^{-1} . ^1H NMR (CDCl_3): δ 7.65-7.26 (14H, m, Ph" and biphenyl" protons), 5.77 (1H, m, 2-methine proton), 2.17 (2H, m, 3-methylene protons), 1.60 (1H, m, 4-methine proton), 1.00-0.90 (6H, m, 4, 4-dimethyl protons). ESI-MS (negative): m/z 486 (M^- -H). HRMS ($\text{C}_{28}\text{H}_{24}\text{NO}_3\text{S}_2$) [$\text{M} - \text{H}$] $^-$: found m/z 486.1196, calcd m/z 486.1196; RP-HPLC method MA3, minor isomer t_R = 22.783 min (39.89%) and major isomer t_R = 23.750 min (60.11%); method MB3, minor isomer t_R = 23.317 min (42.08%) and major isomer t_R = 24.317 min (57.92%).

2-Propenyl 2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-propanoate (3l)

(66%) Yellow powder. TLC (Hexane / CH_2Cl_2 = 1:1), R_f 0.50. m.p. 105-6 $^\circ\text{C}$. ^1H NMR (CDCl_3): δ 7.63 (1H, s, 5'-dene proton), 7.62 (2H, d, J = 8.4 Hz, 2" and 6" Ph protons), 7.35 (2H, d, J = 8.4 Hz, 3" and 5" Ph protons), 5.87 (1H, m, 2-methine proton), 5.73 (1H, m, $\text{CH}_2\text{CH}=\text{CH}_2$ proton), 5.30 and 5.23 (2H, d and d, J = 17.4 Hz and J = 9.6 Hz, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 4.66 (2H, m, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 1.69 (3H, d, J = 9.6 Hz, 3-methyl protons); ESI-MS (positive): m/z 412, 414 (M^+ +H); 368, 370 (M^+ +H- CO_2). HRMS ($\text{C}_{16}\text{H}_{14}\text{BrNO}_3\text{S}_2\text{Na}$) [$\text{M} + \text{Na}$] $^+$: found m/z 433.9504, calcd m/z 433.9495; RP-HPLC method MA1, minor isomer t_R = 23.083 min (3.45%) and major isomer t_R = 24.267 min (96.55%); method MB1, minor isomer t_R = 16.917 min (0.95%) and major isomer t_R = 17.70 min (99.05%).

5-(4-Bromobenzylidene)-3-(1-morpholino-1-oxo-3-phenylpropan-2-yl)-4-oxo-2-thioxothiazolidine (3m)

(97%) Yellow oil. TLC (Methanol / CH_2Cl_2 = 1:99), R_f 0.40. ^1H NMR (CDCl_3): δ 7.62 (1H, s, 5'-dene proton), 7.57 (2H, d, J = 8.4 Hz, 2" and 6" Ph protons), 7.35 (2H, d, J = 8.4 Hz, 3" and 5" Ph protons), 5.56 (1H, q, J = 7.5 Hz, 2-methine proton), 3.83 (4H, t, J = 5.4 Hz, N $(\text{CH}_2)_2(\text{CH}_2)_2\text{O}$ protons), 3.07 (4H, t, J = 5.4 Hz, N $(\text{CH}_2)_2(\text{CH}_2)_2\text{O}$ protons), 1.63 (3H, d, J = 7.2 Hz, 3-methyl protons); ESI-MS (positive): m/z 441, 443 (M^+ +H); 397, 399 (M^+ +H- CO_2). HRMS ($\text{C}_{17}\text{H}_{17}\text{BrN}_2\text{O}_3\text{S}_2\text{Na}$) [$\text{M} + \text{Na}$] $^+$: found m/z 462.9758, calcd m/z 462.9761; RP-HPLC method MA1, minor isomer t_R = 20.050 min (8.66%) and major isomer t_R = 21.150

min (91.34%); method MB1, minor isomer t_R = 16.600 min (8.71%) and major isomer t_R = 17.300 min (91.29%).

2-Propenyl 2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-phenylpropanoate (3n)

(82%) Yellow powder. TLC (CH_2Cl_2), R_f 0.54. m.p. 146-7 °C. ^1H NMR (CDCl_3): δ 7.61 (2H, d, J = 8.1 Hz, 2'' and 6'' Ph protons), 7.60 (1H, s, 5'-dene proton), 7.31 (2H, d, J = 8.1 Hz, 3'' and 5'' Ph protons), 7.20 (5H, m, 3-Ph protons), 5.92 (1H, m, $\text{CH}_2\text{CH}=\text{CH}_2$ proton), 5.88 (1H, m, 2-methine proton), 5.30 and 5.25 (2H, d and d, J = 18.5 Hz and J = 10.5 Hz, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 4.69 (2H, d, J = 4.8 Hz, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 3.63 (2H, d, J = 8.4 Hz, 3-methylene protons); ESI-MS (positive): m/z 488, 490 ($\text{M}^+ + \text{H}$); 444, 446 ($\text{M}^+ + \text{H} - \text{CO}_2$). HRMS ($\text{C}_{22}\text{H}_{18}\text{BrNO}_3\text{S}_2\text{Na}$) [$\text{M} + \text{Na}$] $^+$: found m/z 509.9834, calcd m/z 509.9808; RP-HPLC method MA1, minor isomer t_R = 24.700 min (12.28%) and major isomer t_R = 25.600 min (87.72%); method MB1, minor isomer t_R = 17.983 min (9.07%) and major isomer t_R = 19.017 min (90.93%).

2-Propenyl 2-[5-biphenylmethylidene-4-oxo-2-thioxothiazolidin-3-yl]-3-phenylpropanoate (3o)

(83%). Yellow oil. TLC (Hexane / CH_2Cl_2 = 6:4), R_f 0.20. ^1H NMR (CDCl_3): δ 7.64 and 7.60 (4H, d and d, J = 8.1 Hz and J = 8.1 Hz, ($\text{C}_6\text{H}_4\text{C}_6\text{H}_5$)'' protons), 7.62 (1H, s, 5'-dene proton), 7.45 (5H, m, ($\text{C}_6\text{H}_4\text{C}_6\text{H}_5$)'' protons), 7.30 (5H, m, 3-Ph protons), 5.93 (1H, m, $\text{CH}_2\text{CH}=\text{CH}_2$ proton), 5.89 (1H, m, 2-methine proton), 5.30 and 5.25 (2H, d and d, J = 17.8 Hz and J = 10.5 Hz, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 4.69 (2H, d, J = 5.4 Hz, $\text{CH}_2\text{CH}=\text{CH}_2$ protons), 3.66 (2H, d, J = 7.8 Hz, 3-methylene protons). ESI-MS (positive): m/z 486 ($\text{M}^+ + \text{H}$); 442 ($\text{M}^+ + \text{H} - \text{CO}_2$). HRMS ($\text{C}_{28}\text{H}_{23}\text{NO}_3\text{S}_2\text{Na}$) [$\text{M} + \text{Na}$] $^+$: found m/z 508.1028, calcd m/z 508.1067; RP-HPLC method MA1, minor isomer t_R = 26.233 min (15.50%) and major isomer t_R = 27.083 min (84.50%); method MB1, minor isomer t_R = 19.167 min (13.53%) and major isomer t_R = 19.950 min (86.47%).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References and notes

1. Pinedo, HM.; Giaccone, G. Cambridge University Press; 1998. p. 199
2. Kiechle FL, Zhang X. Clin. Chim. Acta 2002;326:27. [PubMed: 12417095]
3. Folkman J. Seminars in Cancer Biology 2003;13:159. [PubMed: 12654259]
4. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN. Cancer Res 2003;63:1000. [PubMed: 12615715]
5. Chan SL, Lee MC, Tan KO, Yang L, Lee ASY, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC. J. Biol. Chem 2003;278:20453. [PubMed: 12702731]
6. Kim R, Tanabe K, Emi M, Uchida Y, Toge T. Cancer 2005;103:2199. [PubMed: 15830342]
7. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Int. J. Oncol 2003;22:875. [PubMed: 12632082]
8. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Arch. Dermatol. Res 2000;292:225. [PubMed: 10867810]
9. Sanz L, Garcia-Marco JA, Casanova B, Fuente MT, García-Gila M, Garcia-Pardo A, Silva A. Biochem. Biophys. Res. Commun 2004;562. [PubMed: 14975737]
10. Walton KD, Wagner K-U, Rucker EBI, Shillingford JM, Miyoshi K, Hennighausen L. Mech. Dev 2001;109:281. [PubMed: 11731240]

11. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P. *Blood* 1996;87:265. [PubMed: 8547651]
12. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. *Cancer* 1999;85:164. [PubMed: 9921989]
13. Foreman KE, Wrone-Smith T, Boise LH, Thompson CB, Polverini PJ, Simonian PL, Nunez G, Nickoloff BJ. *Am. J. Pathol* 1996;149:795. [PubMed: 8780384]
14. Lee HW, Lee S-S, Lee SJ, Um H-D. *Cancer Res* 2003;63:1093. [PubMed: 12615727]
15. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS. *Br. J. Cancer* 2000;82:178. [PubMed: 10638987]
16. Hartmann K, Artuc M, Baldus SE, Zirbes TK, Hermes B, Thiele J, Mekori YA, Henz BM. *Am. J. Pathol* 2003;163:819. [PubMed: 12937123]
17. Hamner S, Skoglösa Y, Lindholm D. *Neuroscience* 1999;91:673. [PubMed: 10366024]
18. Sorenson CM. *Biochim. Biophys. Acta* 2004;1644:169. [PubMed: 14996501]
19. Gibson L, Holmgren S. p. Huang DCS, Bernard O, Copeland NG, Jenkins NA, Sutherland GR, Baker E, Adams JM, Cory S. *Oncogene* 1996;13:665. [PubMed: 8761287]
20. Reed JC. *Oncogene* 1998;17:3225. [PubMed: 9916985]
21. Adams JM, Cory S. *Trends Biochem. Sci* 2001;26:61. [PubMed: 11165519]
22. Sattler M, Liang H, Nettesheim DN, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. *Science* 1997;275:983. [PubMed: 9020082]
23. Holinger EP, Chittenden T, Lutz RJ. *J. Biol. Chem* 1999;274:13298. [PubMed: 10224090]
24. Wang J, Liu D, Zhang Z, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. *Proc. Natl. Acad. Sci* 2000;97:7124. [PubMed: 10860979]
25. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. *Nat. Cell Biol* 2001;3:173. [PubMed: 11175750]
26. Tzung S, Kim KM, Basañez G, Giedt CD, Simon J, Zimmerberg J, Zhang KYJ, Hockenbery DM. *Nat. Cell Biol* 2001;3:183. [PubMed: 11175751]
27. Chan SL, Lee MC, Tan KO, Yang L, Lee ASY, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC. *J. Biol. Chem* 2003;278:20453. [PubMed: 12702731]
28. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long Y, Roller PP, Yang D, Wang S. *J. Med. Chem* 2001;44:4313. [PubMed: 11728179]
29. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S, Fernandez-Luna JL. *Cancer Res* 2004;64:7947. [PubMed: 15520201]
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DJ, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MB, Zhang H, Fesik SW, Rosenberg SH. *Nature* 2005;435:677. [PubMed: 15902208]
31. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. *Mol. Cell* 2003;11:577. [PubMed: 12667443]
32. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine JL, Korsmeyer SJ. *Science* 2004;305:1466. [PubMed: 15353804]
33. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DCS, Day CL. *EMBO J* 2003;22:1497. [PubMed: 12660157]
34. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong S, Ng S, Fesik SW. *Nature* 1996;381:335. [PubMed: 8692274]
35. Petros AM, Medek A, Nettesheim DJ, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW. *Proc. Natl. Acad. Sci* 2001;98:3012. [PubMed: 11248023]
36. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DCS, Hinds MG. *J. Biol. Chem* 2005;280:4738. [PubMed: 15550399]
37. Gemperli AC, Rutledge SE, Maranda A, Schepartz A. *J. Am. Chem. Soc* 2005;127:1596. [PubMed: 15700967]
38. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DCS. *Mol. Cell* 2005;17:393. [PubMed: 15694340]

39. Yakubich VI, Gritsyuk LV. Farm. Zh 1984;1:40.
40. Petros AM, Olejniczak ET, Fesik SW. Biochim. Biophys. Acta-Mol. Cell Res 2004;1644:83.
41. 2006. <http://www.ncgc.nih.gov/guidance/section5.html>
42. Nikolovska-Coleska Z, Wang R, Fang X, Pan H, Tomita Y, Li P, Roller PP, Krajewski K, Saito NG, Stuckey JA, Wang S. Anal. Biochem 2004;332:261. [PubMed: 15325294]

Figure 1.
Reported inhibitors for Bcl-2 or Bcl-X_L proteins

Figure 2.
Correlation between the calculated binding energy and experimental binding affinity of BHI-1 based Bcl-2 inhibitors

Figure 3.

A. Modeled interaction of BHI-1 based inhibitor **9e** with Bcl-X_L protein.

B. The relative position of amino acid 104, 108, and 122 (side chains are colored purple and distance in Å) to **9e**.

- a) NaOH, CS₂, 23°C, overnight;
b) ClCH₂CO₂Na, 23 °C, 3 hours;
c) HCl, reflux, 12 hours;
d) Benzaldehyde/ketone, NH₄OAc, toluene, reflux, 1-12 hours

Scheme 1.
Synthesis of BHI-1 based Bcl-2 inhibitors **9a-o**

Table 1The binding affinities of Flu-Bak peptide to Bcl-2, Bcl-X_L, and Bcl-w proteins.

K_d ± SD(nM)			
Entry Flu-Bak	Bcl-2 990±100	Bcl-X _L 362±36	Bcl-w 555±41

Table 2The inhibitory capability of reported inhibitors against Flu-Bak binding to Bcl-2, Bcl-X_L, and Bcl-w proteins

Entry	Bcl-2	Ki ± SD (μM) Bcl-X _L	Bcl-w
Antimycin A ₃	124±10.6	127±16.3	127±11.9
Chelerythrine	171±24.3	96±8.9	106±6.3
Gossypol	10.1±0.9	24.7±1.8	17.7±1.3
HA14-1	254±17.2	86.2±7.9	210±18
BHI-1	43.4±3.9	133±7.6	124±12.5

Table 3
The inhibitory capability of BHI-1 based candidates against Flu-Bak binding to Bcl-2, Bcl-X_L, and Bcl-w proteins

Entry	R ₁	R ₂	R ₃	R ₄	Bcl-2	Ki ± SD(μM) Bcl-X _L	Bcl-w
BHI-1							
9a	2-Propyl	H	Br	H	43.4±3.9	133±7.6	124±12.5
9b	Me	H	Br	H	115±8.4	374±16.3	243±14.7
9c	CH ₃ S(CH ₂) ₂	H	Br	H	69.6±4.9	134±20.3	88±14.2
9d	3-Indolyl-CH ₂	H	Br	H	2.85±0.21	32.8±2.7	54.2±5.5
9e	C(O)OH(CH ₂) ₂	H	Br	H	320±21.7	848±39.0	610±31.4
9f	ArCH ₂	H	Br	H	14.2±1.2	5.35±0.39	21.5±1.8
9g	ArCH ₂	n-Butyl	H	H	12±0.8	27.9±2.7	41.1±3.7
9h	(CH ₃) ₂ CHCH ₂	H	Br	H	7.43±0.65	2.99±0.18	31.2±3.8
9i	(CH ₃) ₂ CHCH ₂	n-Butyl	H	H	13.5±0.6	41.3±4.2	24.1±1.7
9j	(CH ₃) ₂ CHCH ₂	Me	H	H	21.2±1.6	128.2±5.9	58.3±4.2
9k	(CH ₃) ₂ CHCH ₂	Phenyl	H	H	57.8±4.6	68.8±5.5	61.9±6.9
9l	(CH ₃) ₂ CHCH ₂	Phenyl	Ar	H	1.95±0.13	8.7±0.46	6.98±0.38
9m	Me	H	Br	2-Propenyl	192±12.4	268±18.4	>1000
9n	Me	H	Br	N-Morpholinyl	70.0±4.4	228±19.7	146±17.6
9o	ArCH ₂	H	Br	2-Propenyl	>1000	244±20.1	56.8±2.9
9o	ArCH ₂	H	Ar	2-Propenyl	260±19.7	176±14.6	116±11.8

Table 4Non-conserved amino acids in the hydrophobic cleft of Bcl-2, Bcl-X_L, and Bcl-w.

	104	108	122
Bcl-X _L	Ala	Leu	Ser
Bcl-2	Asp	Met	Arg
Bcl-w	Thr	Leu	Arg